

From: [REDACTED] > On Behalf Of 340B Communications (no-reply)
Sent: Thursday, May 26, 2022 2:04 PM
Subject: 340B Manufacturer Data Sharing Notification

The Optum logo is displayed in a large, bold, orange font on a light blue background.

Manufacturer Data Sharing Notification

Hello Valued Partner,

Optum is here for you and would like to reaffirm our commitment to serve you. We are aware that drug manufacturers may request that you share certain contract pharmacy claims data related to 340B eligible prescriptions. As you know, such claims data includes information that is protected under applicable law and the terms of our agreement. If you elect to participate in such pharmaceutical manufacturer programs, we have outlined the way by which you can release certain data to pharmaceutical manufacturers.

As a condition of Optum's consent to disclose our data, Optum requires you to provide us the below:

- Name of the pharmaceutical manufacturer;
- Date request received;
- Specific data points to be shared;
- Date range of claims;
- Date by which you intend to share the data;
- Method to be used to share the data;
- Data is secure and de-identified in accordance with applicable privacy laws; and
- Whether the pharmaceutical manufacturer and any vendors handling the data have represented to you that it cannot combine de-identified data with other data either in its possession or the

possession of a third-party vendor to identify individual patients.

If you have already provided data to any pharmaceutical manufacturers, please notify us with the above information as soon as possible. Optum is open to supporting lookbacks for the time that your program may have been disrupted.

These items are necessary to protect patients' protected health information as well as confidential information as defined in your 340B Pharmacy Services Agreement with Optum. Optum's consent to disclose any data is contingent on individual patients not being identified as a result of the disclosure. If you provide any data to pharmaceutical manufacturers, then you, either directly or through the drug manufacturer (or third-party vendor), are confirming that individual patients cannot be identified as a result of such disclosure.

Please know that we are committed to supporting the 340B Program and serving as your contract pharmacy. If your Legal, Compliance, or Privacy Departments would like to discuss this matter in more detail or any concerns with one of our attorneys, please notify your account manager and we will be glad to make one available.

Sincerely,
Your OptumRx 340B Team

© 2022 Optum, Inc. All rights reserved.

This e-mail, including attachments, may include confidential and/or proprietary information, and may be used only by the person or entity to which it is addressed. If the reader of this e-mail is not the intended recipient or intended recipient's authorized agent, the reader is hereby notified that any dissemination, distribution or copying of this e-mail is prohibited. If you have received this e-mail in error, please notify the sender by replying to this message and delete this e-mail immediately.